ReviewInfectious diseases and therapy2020
A Comprehensive Review of Meningococcal Disease Burden in India.
Review in Infectious diseases and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Meningococcal meningitis in India: An expert consensus on use of MCVs.Human vaccines & immunotherapeutics · 2026Pooled it
- Epidemiological trends and neurological outcomes of pediatric central nervous system infections in rural part of western India.World journal of clinical pediatrics · 2026Article
- Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India.Cureus · 2026Review
- Meningococcal Sepsis in Close Family Contact of Umrah Pilgrim to Mecca Despite Pre-Travel Meningococcal Vaccination.Indian journal of pediatrics · 2025Article
- Article
- Meningococcal disease within the Gulf Cooperation Council Countries.Human vaccines & immunotherapeutics · 2023Review
- Review
- Review of the unmet medical need for vaccination in adults with immunocompromising conditions: An Indian perspective.Human vaccines & immunotherapeutics · 2023Review
- Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India.Human vaccines & immunotherapeutics · 2022Article
- Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review.Infectious diseases and therapy · 2022Review
- A Modern Perspective on Vaccinating Healthcare Service Providers in India: A Narrative Review.Infectious diseases and therapy · 2022Review
- Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination.Infectious diseases and therapy · 2021Review
- Mass gatherings: a review of the scope for meningococcal vaccination in the Indian context.Human vaccines & immunotherapeutics · 2021Review
- Meningococcal Disease Burden in India: A Systematic Review and Meta-Analysis.Microbiology insights · 2021Review
- Structural characterization of a nonhydrolyzing UDP-GlcNAc 2-epimerase from Neisseria meningitidis serogroup A.Acta crystallographica. Section F, Structural biology communications · 2020Article
- Need to Study the Health Impact and Economics of Adult Vaccination with India in Focus.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
- A systematic literature review on the prevalence and etiology of meningitis among critically ill and hospitalized patients in India.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMeningococcal disease caused by Neisseria meningitidis has a high case fatality rate. Of 12 distinct serogroups, A, B, C, W-135 (W) and Y cause the majority of infections. The meningococcal disease burden and epidemiology in India are not reliably known. Hence, we performed a narrative review with a systematically conducted search to summarize information on meningococcal disease burden and epidemiology and vaccination recommendations for meningococcal disease in India.
methodsA search of Medline and Embase databases was undertaken to identify relevant publications published in the last 25 years.
resultsResults from 32 original publications, 11 of which were case reports, suggest a significant burden of meningococcal disease and related complications. Meningococcal disease is increasingly reported among adolescents and adults, and large outbreaks have been reported in this population. Meningococcal disease in India is caused almost exclusively by serogroup A; serogroups B, C, W and Y have also been documented. Meningococcal disease burden data remain unreliable because of limited disease surveillance, insufficient laboratory capacity, misdiagnosis and prevalence of extensive antibiotic use in India. Lack of access to healthcare also increases under-reporting, thus bringing the reliability of the data into question. Conjugate meningococcal vaccines are being used for disease prevention by national governments and immunization programs globally. In India, meningococcal vaccination is recommended only for certain high-risk groups, during outbreaks and for international travelers such as Hajj pilgrims and students pursuing studies abroad.
conclusionMeningococcal disease is prevalent in India but remains grossly underestimated and under-reported. Available literature largely presents outbreak data related to serogroup A disease; however, non-A serogroup disease cases have been reported. Reliable epidemiologic data are urgently needed to inform the true burden of endemic disease. Further research into the significance of meningococcal disease burden can be used to improve public health policy in India. Fig. 1 Plain language summary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.